ArticleMicrobial biotechnology2026
Characterisation of a Novel Jumbo Lytic Aeromonas dhakensis Bacteriophage P19 and Its Endolysin.
Article in Microbial biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Polycationic Peptide Engineering of Phage Endolysins Expands Host Range and Enhances Antibacterial and Antibiofilm Activities Against Bacillus Species.Biotechnology and bioengineering · 2026Article
- Characterisation of a Novel Jumbo Lytic Aeromonas dhakensis Bacteriophage P19 and Its Endolysin.Microbial biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Aeromonas dhakensis is an emerging multidrug-resistant (MDR) bacterial pathogen that presents significant threats to public health and aquaculture. This study reports the isolation and comprehensive characterisation of jumbo bacteriophage P19. It is a lytic phage with a long, contractile tail and is placed in the genus Ceceduovirus of the family Straboviridae. P19 possesses a large genome typical of jumbo phages, which likely contributes to its enhanced replication efficiency and adaptability. P19 exhibited strong lytic activity with a high efficiency of plating (EOP) against multiple A. dhakensis strains, a burst size of approximately 50 plaque-forming units (PFU) per cell, and a latent period of 30 min. It remained highly stable across pH 6-10 and temperatures up to 60°C. Genomic analysis revealed a 228 kb genome with 414 open reading frames (ORFs) and absence of genes related to lysogeny, antibiotic resistance or virulence, indicating its potential for safe therapeutic and biocontrol applications. ORF_358 encodes a stable and soluble T4-type lysozyme endolysin (molecular weight 18.8 kDa) belonging to the glycoside hydrolase family 24. Molecular docking analysis demonstrated strong binding affinity (-6.4 kcal/mol) between P19_358 and the peptidoglycan NAG-NAM dimer. Recombinant P19_358 endolysin exhibited 99.98% relative lytic activity against Gram-positive bacterium Bacillus subtilis at a concentration of 75 μg/mL without EDTA pre-treatment; whereas, it showed broad-spectrum antibacterial activity against several Gram-negative pathogens, including A. dhakensis, Shigella flexneri, Salmonella Typhimurium, Pseudomonas aeruginosa and Escherichia coli, with relative activity ranging from 71% to 97% following pre-treatment with 100 mM EDTA. These findings collectively indicate that phage P19 and its endolysin P19_358 possess potent lytic activity and favourable stability profiles, supporting their development as promising antimicrobial agents against MDR Gram-negative pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.